ABSTRACT
The effect of macrolides on the superoxide (O2 −) production by neutrophils was studied. Resting neutrophils become primed by lipopolysaccharide (LPS) or N-formyl-methionyl-leucyl-phenylalanine (fMLP), and primed neutrophils generate O2 − in response to fMLP or adhesion, respectively. Both LPS-primed fMLP-stimulated O2 − generation by macrolide-treated neutrophils and adhesion-stimulated O2 − generation by macrolide-treated fMLP-primed neutrophils were inhibited. Macrolide inhibition of O2 − generation was dependent on serum or pH. Serum could be substituted by NaHCO3. The intensity of inhibition was azithromycin = roxithromycin > clarithromycin > erythromycin, in that order. Non-antimicrobial derivatives of erythromycin, that is, EM703 and EM900, inhibited O2 − generation at pH 7.4. NH4Cl abolished the activity of azithromycin (AZ) only when added to neutrophils with AZ but not after incubation with AZ, suggesting that NH4Cl prevented the influx of AZ. AZ did not affect the expression of alkaline phosphatase, CD11b, and cytochrome b558 in both resting and LPS-primed neutrophils. These results suggested that macrolides did not affect granule mobilization but inhibited O2 − generation selectively.
Similar content being viewed by others
Abbreviations
- AZ:
-
Azithromycin
- CL:
-
Clarithromycin
- DMSO:
-
Dimethyl sulfoxide
- ER:
-
Erythromycin
- FITC:
-
Fluorescein isothiocyanate
- fMLP:
-
N-formyl-methionyl-leucyl-phenylalanine
- HEPES:
-
H-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid
- LPS:
-
Lipopolysaccharide
- IgG:
-
Immunoglobulin G
- MFI:
-
Mean channel of fluorescence intensity
- mAb:
-
Monoclonal antibody
- PBS:
-
Phosphate-buffered saline
- PMA:
-
Phorbol myristate acetate, O2 −, superoxide anion
- RO:
-
Roxithromycin
REFERENCES
Labro, M.T. 2004. Cellular and molecular effects of macrolides on leukocyte function. Current Pharmaceutical Design 10: 3067–3080.
Ianaro, A., A. Ialenti, P. Maffia, L. Sautebin, L. Rombolaá, R. Carnuccio, T. Iuvone, F. D’Acquisto, and M. Di Rosa. 2000. Anti-inflammatory activity of macrolide antibiotics. The Journal of Pharmacology and Experimental Therapeutics 292: 156–163.
Desaki, M., H. Okazaki, T. Sunazuka, S. Omura, K. Yamamoto, and H. Takizawa. 2004. Molecular mechanisms of anti-inflammatory action of erythromycin in human bronchial epithelial cells: Possible role in the signaling pathway that regulates nuclear factor-κB activation. Antimicrobial Agents and Chemotherapy 48: 1581–1585.
Otsu, K., H. Ishinaga, S. Suzuki, A. Sugawara, T. Sunazuka, S. Omura, H. Jono, and K. Takeuchi. 2011. Effects of a novel nonantibiotic macrolide, EM900, on cytokine and mucin gene expression in a human airway epithelial cell line. Pharmacology 88: 327–332.
Bosnar, M., Z. Kelnerić, V. Munić, V. Eraković, and M.J. Parnham. 2005. Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin. Antimicrobial Agents and Chemotherapy 49: 2372–2377.
Hand, W.L., and D.L. Hand. 2001. Characteristics and mechanisms of azithromycin accumulation and efflux in human polymorphonuclear leukocytes. International Journal of Antimicrobial Agents 18: 419–425.
Gladue, R.P., and M.E. Snider. 1990. Intracellular accumulation of azithromycin by cultured human fibroblasts. Antimicrobial Agents and Chemotherapy 34: 1056–1060.
Mittal, M., M.R. Siddiqui, K. Tran, S.P. Reddy, and A.B. Malik. 2014. Reactive oxygen species in inflammation and tissue injury. Antioxidants and Redox Signaling 20: 1126–1167.
Sheppard, F.R., M.R. Kelher, E.E. Moore, N.J.D. Mclaughlin, A. Banerjee, and C.C. Silliman. 2005. Structural organization of the neutrophil NADPH oxidase: phosphorylation and translocation during priming and activation. Journal of Leukocyte Biology 78: 1025–1042.
Labro, M.T., J. El Benna, and C. Babin-Chevayec. 1989. Comparison of the in-vitro effect of several macrolides on the oxidative burst of human neutrophils. Journal of Antimicrobial Chemotherapy 24: 561–572.
Hand, W.L., D.L. Hand, and N.L. King-Thompson. 1990. Antibiotic inhibition of the respiratory burst response in human polymorphonuclear leukocytes. Antimicrobial Agents and Chemotherapy 34: 863–870.
Hand, W.L., and D.L. Hand. 1993. Interaction of dirithromycin with human polymorphonuclear leukocytes. Antimicrobial Agents and Chemotherapy 37: 2557–2562.
Anderson, R., A.J. Theron, and C. Feldman. 1996. Membrane-stabilizing, anti-inflammatory interactions of macrolides with human neutrophils. Inflammation 20: 693–705.
Levert, H., B. Gressier, I. Moutard, C. Brunet, T. Dine, M. Luyckx, M. Cazin, and J.C. Cazin. 1998. Azithromycin impact on neutrophil oxidative metabolism depends on exposure time. Inflammation 22: 191–201.
Abdelghaffar, H., C. Babin-Chevaye, and M.T. Labro. 2005. The macrolide roxithromycin impairs NADPH oxidase activation and alters translocation of its cytosolic components to the neutrophil membrane in vitro. Antimicrobial Agents and Chemotherapy 49: 2986–2989.
Hand, W.L., D.L. Hand, and Y. Vasquez. 2007. Increased polymorphonuclear leukocyte respiratory burst function in type 2 diabetes. Diabetes Research and Clinical Practice 76: 44–50.
GLADUE, R.P., G.M. Bright, R.E. Isaacson, and M.F. Newborg. 1989. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: Possible mechanism of delivery and release at sites of infection. Antimicrobial Agents and Chemotherapy 33: 277–282.
Pascual, A., G. López-López, J. Aragón, and E.J. Perea. 1990. Effect of azithromycin, roxithromycin and erythromycin on human polymorphonuclear leukocyte function against Staphylococcus aureus. Chemotherapy 36: 422–427.
Pascual, A., M. Carmen Conejo, I. Garcia, and E.J. Perea. 1995. Factors affecting the intracellular accumulation and activity of azithromycin. Journal of Antimicrobial Chemotherapy 35: 85–93.
Mcintire, F.C., G.H. Barlow, H.W. Sievert, R.A. Finley, and A.L. Yoo. 1969. Study on a lipopolysaccharide from Escherichia coli. Heterogeniety and mechanism of reversible inactivation by sodium deoxycholate. Biochemistry 8: 4063–4067.
Nakamura, M., M. Murakami, T. Koga, Y. Tanaka, and S. Minakami. 1987. Monoclonal antibody 7D5 raised to cytochrome b558 of human neutrophils: Immunocytochemical detection of the antigen in peripheral phagocytes of normal subjects, patients with chronic granulomatous disease, and their carrier mothers. Blood 69: 1404–1408.
Aida, Y., and M.J. Pabst. 1991. Neutrophil responses to lipopolysaccharide. Effect of adherence on triggering and priming of the respiratory burst. Journal of Immunology 146: 1271–1276.
Aida, Y., and M.J. Pabst. 1990. Priming of neutrophils by lipopolysaccharide for enhanced release of superoxide. Requirement for plasma but not for tumor necrosis factor-α. Journal of Immunology 145: 3017–3025.
Borregaard, N., and J.B. Cowland. 1997. Granules of human neutrophilic polymorphonuclear leukocyte. Blood 89: 3503–3521.
Aida, Y., K. Kusumoto, K. Nakatomi, H. Takada, M.J. Pabst, and K. Maeda. 1995. An analogue of lipid A and LPS from Rhodobacter sphaeroides inhibits neutrophil response to LPS by blocking receptor recognition of LPS and by depleting LPS-binding protein in plasma. Journal of Leukocyte Biology 58: 675–682.
Borregaard, N., L.J. Miller, and T.A. Springer. 1987. Chemoattractant-regulated mobilization of a novel intracellular compartment in human neutrophils. Science 237: 1204–1206.
Deleo, F.R., J. Renee, S. Mccormik, M. Nakamura, M. Apicella, J.P. Weiss, and W.M. Nauseef. 1998. Neutrophils exposed to bacterial lipopolysaccharide upregulate NADPH oxidase assembly. Journal of Clinical Investigation 101: 455–463.
Hand, W.L., N. King-Thompson, and J.W. Holman. 1987. Entry of roxithromycin (RU 965), imipenem, cefotaxime, trimethoprim, and metronidazole into human polymorphonuclear leukocytes. Antimicrobial Agents and Chemotherapy 31: 1553–1557.
Li, Y.J.L., A. Azuma, J. Usuki, S. Abe, K. Matsuda, T. Sunazuka, T. Shimizu, Y. Hirata, H. Inagaki, T. Kawada, S. Takahashi, S. Kudoh, and S. Omura. 2006. EM703 improves bleomycin-induced pulmonary fibrosis in mice by the inhibition of TGF-β signaling in lung fibroblasts. Respiratory Research 7: 16–28.
Ikeda, H., T. Sunazuka, H. Suzuki, Y. Hamasaki, S. Yamazaki, S. Omura, and A. Hatamochi. 2008. EM703, the new derivative of erythromycin, inhibits transcription of type I collagen in normal and scleroderma fibroblasts. Journal of Dermatological Science 49: 195–205.
Klempner, M.S., and B. Styrt. 1983. Alkalinizing the intralysosomal pH inhibits degranulation of human neutrophils. Journal of Clinical Investigation 72: 1793–1800.
Jinnouchi, A., Y. Aida, K. Nozoe, K. Maeda, and M.J. Pabst. 2005. Local anesthetics inhibit priming of neutrophils by lipopolysaccharide for enhanced release of superoxide: suppression of cytochrome b558 expression by disparate mechanisms. Journal of Leukocyte Biology 78: 1356–1365.
ACKNOWLEDGMENTS
We thank Pfizer Pharmaceutical Inc., Tokyo, Japan, for providing azithromycin; Toshiaki Sunazuka of The Kitasato Institute for providing the erythromycin derivatives EM703 and EM900; Michio Nakamura of Nagasaki University for providing the anti-cytochrome b558 antibody; Floyd McIntire for providing the Escherichia coli LPS; and Tomofumi Miyamoto of Kyushu University and Sadafumi Omura of Technology Licensing Organization, Kyushu, for their helpful comments and encouragement.
This work was supported by a grant-in-aid (26463137) to T.F. from the Ministry of Health of Japan.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Nozoe, K., Aida, Y., Fukuda, T. et al. Mechanisms of the Macrolide-Induced Inhibition of Superoxide Generation by Neutrophils. Inflammation 39, 1039–1048 (2016). https://doi.org/10.1007/s10753-016-0333-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10753-016-0333-3